The more I research SIBO and work through complex gastrointestinal cases, the more I think we are asking the wrong question. I keep seeing the same pattern: someone develops bloating, distention, abdominal pain, constipation, diarrhea, food intolerance, reflux, or major motility problems, a breath test comes back positive, rifaximin is prescribed, symptoms improve for a while, and then everything returns. Another breath test follows, then another round of rifaximin, perhaps herbal antimicrobials, biofilm protocols, more dietary restriction, and eventually the entire conversation becomes focused on how to kill the bacteria more aggressively. But I think the more important question is why those bacteria were able to accumulate in the small intestine in the first place. SIBO is not a rifaximin deficiency. The small intestine normally controls microbial abundance through a highly coordinated combination of motility, the migrating motor complex, gastric acid, bile acids, pancreatic secretions, mucosal immunity, normal anatomy, ileocecal compartmentalization, enteric neural signaling, interstitial cells of Cajal, smooth-muscle function, and autonomic regulation. When one or more of these systems fails, the ecological environment changes. From a basic systems perspective, microbial accumulation depends not only on how quickly bacteria reproduce but also on how effectively the intestine removes them.
When intestinal clearance slows, residence time rises, organisms have more time to replicate, ferment substrates, interact metabolically, alter bile-acid chemistry, generate gases and metabolites, and occupy niches that normally would not sustain a large microbial population. In that situation, the fundamental problem may not be unusually aggressive bacteria at all; it may be a failure of the intestine’s washout machinery. This is where the migrating motor complex becomes especially important. Between meals, the stomach and small intestine generate organized fasting motor activity that helps sweep residual food, secretions, cellular debris, and microorganisms distally. If this system becomes impaired, intestinal contents remain in place longer and the physical conditions for microbial expansion become progressively more favorable. Rifaximin can reduce the bacterial population, sometimes very effectively, but it does not automatically repair an abnormal migrating motor complex, regenerate damaged enteric neurons, restore autonomic signaling, reconstruct altered anatomy, normalize smooth-muscle function, or correct a structural reservoir.
It can change the population without necessarily changing the habitat that selected for that population. Once we start asking why motility failed, the discussion moves far beyond microbiology. Intestinal propulsion is the final output of a complex electrical and mechanical network involving the enteric nervous system, excitatory and inhibitory neurotransmission, interstitial cells of Cajal, PDGFRα-positive cells, smooth muscle, autonomic pathways, enteroendocrine signaling, immune cells, vascular supply, and cellular bioenergetics. A disturbance anywhere along this network can create impaired propulsion and prolonged luminal residence time. In some people the primary problem may be enteric neuropathy; in others it may be autonomic dysfunction, altered anatomy after surgery, adhesions, diverticula, an obstruction, severe constipation, impaired gastric emptying, medication effects, pancreatic dysfunction, altered bile physiology, immune deficiency, or a systemic neuromuscular disorder. These patients may all receive the same label of “SIBO,” but biologically they may have completely different diseases. This is especially important when SIBO occurs alongside POTS, dysautonomia, abnormal sweating, urinary autonomic symptoms, gastroparesis, neuropathic pain, orthostatic abnormalities, or widespread motility dysfunction. Small autonomic fibers include unmyelinated C fibers and thinly myelinated Aδ fibers, and autonomic neuropathy can certainly affect gastrointestinal physiology, although a reduced small-fiber density on a skin biopsy does not by itself prove damage to the enteric nervous system because those are different anatomical compartments. Still, when objective autonomic abnormalities coexist with gastrointestinal dysmotility, it becomes reasonable to investigate whether recurrent overgrowth is downstream of impaired neural control rather than treating it as an isolated luminal infection. The same reasoning applies to bile acids. Bile is not simply a digestive detergent; bile acids participate in microbial selection, epithelial signaling, metabolism, secretion, and motility through receptors such as FXR and TGR5, while intestinal microbes themselves transform bile acids through deconjugation and other enzymatic reactions. This creates a bidirectional relationship in which impaired motility can alter microbial ecology, altered microbial ecology can change bile-acid composition, and altered bile-acid signaling can further modify the intestinal environment.
None of this means that every SIBO case has a complex neurological or bile-acid disorder, but it does mean that repeatedly treating bacterial abundance without investigating the physiological systems controlling that abundance can become a therapeutic loop. The same caution applies to the increasingly common explanation that every recurrence must be due to “biofilm.” Biofilms are real biological structures and microbes are highly sophisticated organisms capable of signaling, metabolic cooperation, niche adaptation, and changes in antimicrobial susceptibility, but treatment failure should not automatically be interpreted as evidence that we simply failed to kill hard enough. If the intestine remains anatomically stagnant or neurologically dysmotile, recurrence does not require a mysterious resistant biofilm; normal microbial replication in an abnormal habitat may be enough. We should also remember that SIBO diagnosis itself is imperfect. Breath testing is indirect, transit time varies substantially between individuals, and abnormal transit can complicate interpretation, so a positive test should never replace an evaluation of the physiology producing the symptoms. This is why I think the clinical sequence needs to change. Instead of immediately asking which antibiotic, herbal antimicrobial, or biofilm disruptor should come next, we should first ask what happened to the migrating motor complex, whether gastric and small-bowel transit are abnormal, whether there is autonomic or enteric dysfunction, whether anatomy has been altered, whether there is a stagnant reservoir, whether gastric acid, pancreatic secretion, bile physiology, or mucosal immunity is impaired, whether medications are slowing propulsion, and whether a systemic neurological, metabolic, inflammatory, or connective-tissue process is affecting the gut.
Rifaximin can absolutely have a role, and reducing microbial burden may sometimes be necessary, especially when the upstream disorder cannot be immediately corrected, but antimicrobial therapy should be understood for what it is: a way of modifying the microbial population, not automatically a repair mechanism for the physiological system that allowed the population to expand. That is the distinction I think is being missed. In many recurrent cases, SIBO may not be the primary disease at all. It may be the ecological fingerprint of a small intestine that has lost some part of its ability to control microbial geography. If that is true, then continuing the cycle of positive test, rifaximin, temporary improvement, relapse, and another kill phase without investigating why intestinal clearance failed is not really solving the problem; it is repeatedly resetting the downstream consequence while leaving the upstream biology intact. The question should therefore not only be, “What can kill the bacteria?” The more important question may be, “What failed in this intestine that allowed them to live there in the first place?